Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease

Neurology

Volumn 76, Issue 3, 2011, Pages 247-252

  Prodan, C I ^a   Ross, E D ^a   Stoner, J A ^b   Cowan, L D ^b   Vincent, A S ^d   Dale, G L ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Biostatistics and Epidemiology ^*  (United Kingdom)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; COATED PLATELET; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INCIDENCE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; THROMBOCYTE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PROTEIN PRECURSOR; BLOOD PLATELETS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MALE; ODDS RATIO; PLATELET ACTIVATION; RISK FACTORS;

EID: 78751608012     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182074bd2     Document Type: Article

References (36)

1. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415:175-179.
2. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: Effects of iono-phore A23187, thrombin, collagen and convulxin. Blood 2000;95:1694-1702.
3. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005;3:2185-2192.
4. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL. Coated-platelets retain amyloid precursor protein on their surface. Platelets 2006;17:56-60.
5. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets correlate with disease progression in Alzheimer disease. J Neurol 2007;254:548-549.
6. Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer's disease correlates with coated-platelet levels-a longitudinal study. Transl Res 2008;152: 99-102.
7. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets are higher in amnestic versus non-amnestic patients with mild cognitive impairment. Alzheimer Dis Assoc Disord 2007;21:259-261.
8. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
9. Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007;27:22-31.
10. Ross ED, Shah SN, Prodan CI, Monnot M. Changing relative prevalence of Alzheimer disease versus non-Alzheimer disease dementias: have we underestimated the looming dementia epidemic? Dement Geriatr Cogn Dis-ord 2006;22:273-277.
11. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure: report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 2006;77: 714-718.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-944.
15. Prodan CI, Joseph PM, Vincent AS, Dale GL. Coated-platelets in ischemic stroke: Differences between lacunar and cortical stroke. J Thromb Haemost 2008;6:609-614.
16. Prodan CI, Stoner JA, Cowan LD, Dale GL. Lower coated-platelet levels are associated with early hemorrhagic transformation in patients with non-lacunar brain infarction. J Thromb Haemost 2010;8:1185-1190.
17. Prodan CI, Joseph PM, Vincent AS, Dale GL. Coated-platelet levels are influenced by smoking, aspirin and selective serotonin reuptake inhibitors. J Thromb Haemost 2007;5:2149-2151.
18. Norgard NB, Saya S, Hann CL, Hennebry TA, Schechter E, Dale GL. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheter-ization. J Cardiovasc Pharmacol 2008;52:536-539.
19. Prodan CI, Ross ED, Vincent AS, Dale GL. Differences in coated-platelet production between frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord 2009;23:234-237.
20. NCSS, LLC [computer program]. Kaysville, UT: PASS; 2008.
21. Katzman R. The prevalence and malignancy of Alzheimer disease: a major killer [editorial]. Arch Neurol 1976;33: 217-218.
22. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
23. Muck-Seler D, Presecki P, Mimica N, et al. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1226-1231.
24. Shi C, Guo K, Yew DT, et al. Effects of ageing and Alzheimer's disease on mitochondrial function of human platelets. Exp Gerontol 2008;43:589-594.
25. Vignini A, Nanetti L, Moroni C, et al. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neu-robiol Aging 2007;28:987-994.
26. Borroni B, Perani D, Broli M, et al. Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF SPECT analysis. J Neurol 2005; 252:1359-1362.
27. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: A bio-marker for Alzheimer's disease. J Neurol Sci 2006;240:53-58.
28. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
29. Borroni B, DiLuca M, Cattabeni F, Padovani A. Advance on the diagnostic potential of biological markers in the early detection of Alzheimer disease. Neurosci Res Com-mun 2004;35:232-245.
30. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008;7:704-714.
31. Mortimer JA, Petersen RC. Detection of prodromal Alzheimer's disease. Ann Neurol 2008;64:479-480.
32. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 2006;129:2823-2839.
33. Prodan CI, Vincent AS, Padmanabhan R, Dale GL. Coated-platelet levels are low in patients with spontaneous intracerebral hemorrhage. Stroke 2009;40:2578-2580.
34. Prodan CI, Vincent AS, Dale GL. Coated platelet levels correlate with bleed volume in patients with spontaneous intracerebral hemorrhage. Stroke 2010;41:1301-1303.
35. Valaydon ZS, Lee P, Dale GL, et al. Increased coated-platelet levels in chronic haemodialysis patients. Nephrol-ogy 2009;14:148-154.
36. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.